Pharma and Life Sciences
Sustainable growth through strategic clarity and operational excellence
Pharmaceutical and biotech companies, as well as investors in the life sciences sector, are operating in an increasingly demanding environment. Rising R&D costs, intensifying competition and continuously evolving regulatory and reimbursement frameworks are reshaping the conditions for sustainable growth and transaction success. At the same time, expectations regarding the long-term economic viability of medical innovation continue to grow.
In this environment, success depends on more than scientific progress alone. Companies and investors need a clear view on market potential, portfolio quality, commercialization pathways and operational scalability. Strong and well-prioritized pipelines, the ability to bring innovations to market maturity and a convincing value proposition for decision-makers, providers and payers are critical.
ZEQ supports pharmaceutical and life sciences companies, investors and portfolio companies in translating strategic ambition into measurable results. From commercial and operational due diligence to portfolio strategy, post-merger integration, operating model design and performance improvement, we help clients navigate complexity, strengthen execution and build sustainable market positions.
Pharma & Life Sciences between innovation pressure, transaction dynamics and increasing complexity
The industry is shaped by scientific progress, structural challenges and increasing investor activity. Typical drivers include:
- Increasing cost pressure: Rising investments in research and development require clear prioritization, disciplined resource allocation and efficient portfolio management.
- Transaction and value creation pressure: Investors need a robust understanding of market attractiveness, scalability, synergy potential and operational improvement levers before and after a transaction.
- Regulatory and market dynamics: Continuously changing frameworks for approval, pricing and reimbursement increase complexity and require adaptive strategies.
- Growing stakeholder complexity: Successful market positioning depends on convincing a broad range of stakeholders, including physicians, hospitals, providers, investors and payers.
- Digital transformation: New digital capabilities are reshaping how companies interact with stakeholders, generate insights and create value beyond the core product.
- Changing commercial models: Traditional sales and communication approaches are reaching their limits, requiring more flexible and digitally supported engagement models.
ZEQ supports clients in mastering these challenges across the full transaction and transformation lifecycle, from strategic assessment to value creation and sustainable execution.
Where we create impact
We create impact where strategic decisions, investment logic and operational reality meet. In the pharmaceutical and life sciences industry, sustainable value is rarely driven by isolated initiatives. It requires alignment across portfolio strategy, commercial model, operating model and transaction execution.
On a strategic level, we support companies and investors in making robust portfolio and growth decisions. This includes assessing market opportunities, evaluating business models, prioritizing assets and defining clear pathways for value creation across the lifecycle.
In transaction contexts, we help clients build transparency before and after investment decisions. We support commercial and operational due diligence, assess scalability and synergy potential and identify value creation levers for portfolio companies.
A critical lever for sustainable impact is the operating model. We help organizations define governance structures, clarify roles and build the capabilities required to deliver at scale. In post-merger integration and transformation programs, we support execution through clear PMO structures, pragmatic tools and disciplined performance steering.
Finally, we drive measurable performance improvement. This includes establishing KPI-based steering models, increasing productivity and optimizing portfolios and processes. The goal is to create transparency, enable better decision-making and support continuous improvement.
Examples of our work
The following project examples illustrate how we translate strategic concepts into measurable results across portfolio, commercial and transformation topics.
Post-merger integration (PMI) in pharma environment
- Enabled structured PMI through targeted workshops and governance setup
- Supported portfolio decisions, including divestment of non-strategic products
- Built PMO capabilities, including training, templates and tools for future integrations
Portfolio optimization and strategic fit assessment
- Assessed strategic alignment of acquired products with growth ambitions
- Developed clear decision framework for retain, grow or divest
- Supported execution of carve-out and transfer of selected assets
Commercial model redesign across regions
- Defined regional go-to-market approaches based on market maturity and stakeholder structure
- Strengthened role clarity and governance for commercial leadership
- Improved execution through tailored operating models and performance tracking
Project steering and capability building in transformation programs
- Established governance and reporting structures for large-scale initiatives including Project Management Office (PMO)
- Developed standardized tools and templates to provide scalability
- Trained internal teams to increase execution maturity
Where strategy consulting creates impact
Our work translates strategic concepts and investment theses into tangible impact across three key dimensions. We support pharmaceutical and life sciences companies, investors and portfolio companies in making the right commercial choices, building scalable organizations and improving portfolio performance.
What sets us apart
What differentiates us is the combination of senior expertise, deep industry understanding and strong transaction and transformation experience. Our team brings broad experience from healthcare, pharmaceuticals and life sciences, combining strategic perspective with practical insight into how the industry operates.
We understand the environment our clients work in: complex stakeholder systems, high regulatory pressure, increasing performance expectations and the need to balance innovation with commercial and operational realities. This is particularly relevant in transaction contexts, where investors require a clear view on market potential, scalability, operational risks and value creation opportunities.
A key part of our approach is working closely with clients and portfolio companies rather than developing concepts in isolation. Through co-creation, we help shape strategies, operating models and improvement initiatives with the organization and support their effective anchoring after the transaction or transformation phase.
Clients value our ability to combine senior judgement, methodological strength and hands-on implementation support. This is reflected in three core principles:
- Senior teams with strong industry insights and transaction experience
- Co-creation with management teams to build ownership and support sustainable anchoring
- Practical solutions based on a deep understanding of the healthcare and life sciences ecosystem
This integrated approach helps companies and investors make better decisions, accelerate value creation and sustain results over time.
Success in Pharma and Life Sciences is no longer driven by strategy alone, but by the ability to translate it into consistent execution across portfolio, organization and commercial models.
Dr. Isabelle Heiber
Head of Pharma & Life Sciences
